Methyldopa injection adverse reactions: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Methyldopa}} {{CMG}}; {{AE}} {{AK}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = METHYLDOPATE HYDROCHLORIDE INJECTION, SOLUTIO...")
 
No edit summary
Line 3: Line 3:
{{CMG}}; {{AE}} {{AK}}
{{CMG}}; {{AE}} {{AK}}


==ADVERSE REACTIONS==
[[Sedation]], usually transient, may occur during the initial period of therapy or whenever the dose is increased. [[Headache]], [[asthenia]], or weakness may be noted as early and transient symptoms. However, significant adverse effects due to methyldopa have been infrequent and this agent usually is well tolerated.


The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity.


'''Cardiovascular:''' Aggravation of [[angina pectoris]], [[congestive heart failure]], prolonged [[carotid sinus hypersensitivity]], [[orthostatic hypotension]] (decrease daily dosage), [[edema ]]or weight gain, [[bradycardia]].


'''Digestive:''' [[Pancreatitis]], [[colitis]], [[vomiting]], [[diarrhea]], [[sialadenitis]], [[sore ]]or  black tongue, [[nausea]], [[constipation]], [[distension]], flatus, dryness of mouth.


'''Endocrine:''' [[Hyperprolactinemia]].


<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = METHYLDOPATE HYDROCHLORIDE INJECTION, SOLUTION [AMERICAN REGENT, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5f25053-a9f3-48b9-a412-078f5ee942fd | publisher =  | date =  | accessdate = 10 March 2014 }}</ref>
'''Hematologic:''' [[Bone marrow depression]], [[leukopenia]], [[granulocytopenia]], [[thrombocytopenia]], [[hemolytic anemia]]; positive tests for antinuclear antibody, LE cells, and [[rheumatoid factor]], positive [[Coombs test]].


'''Hepatic:''' Liver disorders including [[hepatitis]], [[jaundice]], abnormal liver function tests (see [[Methyldopa injection  warnings|WARNINGS]]).
'''Hypersensitivity:''' [[Myocarditis]], [[pericarditis]], [[vasculitis]], lupus-like syndrome, drug-related fever, [[eosinophilia]].
'''Nervous System/Psychiatric:''' [[Parkinsonism]], [[Bell's palsy]], decreased mental acuity, involuntary choreoathetotic movements, symptoms of cerebrovascular insufficiency, psychic disturbances including [[nightmares ]]and reversible mild [[psychoses ]]or [[depression]], [[headache]], [[sedation]], [[asthenia ]]or [[weakness]], [[dizziness]], light-headedness, [[paresthesias]].
'''Metabolic:''' Rise in [[BUN]].
'''Musculoskeletal:''' [[Arthralgia]], with or without joint swelling; [[myalgia]].
'''Respiratory:''' Nasal [[stuffiness]].
'''Skin:''' [[Toxic epidermal necrolysis]], [[rash]].
'''Urogenital:''' [[Amenorrhea]], breast enlargement, [[gynecomastia]], [[lactation]], [[impotence]], decreased [[libido]].<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = METHYLDOPATE HYDROCHLORIDE INJECTION, SOLUTION [AMERICAN REGENT, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5f25053-a9f3-48b9-a412-078f5ee942fd | publisher =  | date =  | accessdate = 10 March 2014 }}</ref>





Revision as of 17:00, 10 March 2014

Methyldopa
Methyldopa tablet® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Labels and Packages
Methyldopa injection® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials on Methyldopa
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

ADVERSE REACTIONS

Sedation, usually transient, may occur during the initial period of therapy or whenever the dose is increased. Headache, asthenia, or weakness may be noted as early and transient symptoms. However, significant adverse effects due to methyldopa have been infrequent and this agent usually is well tolerated.

The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity.

Cardiovascular: Aggravation of angina pectoris, congestive heart failure, prolonged carotid sinus hypersensitivity, orthostatic hypotension (decrease daily dosage), edema or weight gain, bradycardia.

Digestive: Pancreatitis, colitis, vomiting, diarrhea, sialadenitis, sore or black tongue, nausea, constipation, distension, flatus, dryness of mouth.

Endocrine: Hyperprolactinemia.

Hematologic: Bone marrow depression, leukopenia, granulocytopenia, thrombocytopenia, hemolytic anemia; positive tests for antinuclear antibody, LE cells, and rheumatoid factor, positive Coombs test.

Hepatic: Liver disorders including hepatitis, jaundice, abnormal liver function tests (see WARNINGS).

Hypersensitivity: Myocarditis, pericarditis, vasculitis, lupus-like syndrome, drug-related fever, eosinophilia.

Nervous System/Psychiatric: Parkinsonism, Bell's palsy, decreased mental acuity, involuntary choreoathetotic movements, symptoms of cerebrovascular insufficiency, psychic disturbances including nightmares and reversible mild psychoses or depression, headache, sedation, asthenia or weakness, dizziness, light-headedness, paresthesias.

Metabolic: Rise in BUN.

Musculoskeletal: Arthralgia, with or without joint swelling; myalgia.

Respiratory: Nasal stuffiness.

Skin: Toxic epidermal necrolysis, rash.

Urogenital: Amenorrhea, breast enlargement, gynecomastia, lactation, impotence, decreased libido.[1]



References

  1. "METHYLDOPATE HYDROCHLORIDE INJECTION, SOLUTION [AMERICAN REGENT, INC.]". Retrieved 10 March 2014.